Zenas BioPharma, Inc.
ZBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $116 | $44 | $197 | $320 |
| Short-Term Investments | $175 | $229 | $116 | $31 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $6 | $5 | $5 | $5 |
| Total Curr. Assets | $297 | $279 | $318 | $356 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $11 | $2 | $2 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $14 | $12 | $13 | $13 |
| Total NC Assets | $25 | $14 | $16 | $14 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $322 | $293 | $334 | $370 |
| Liabilities | – | – | – | – |
| Payables | $6 | $8 | $20 | $17 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $45 | $45 | $28 | $39 |
| Total Curr. Liab. | $52 | $53 | $49 | $57 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $73 | $0 | $0 | $0 |
| Total NC Liab. | $73 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $1 | $1 |
| Total Liabilities | $126 | $53 | $49 | $58 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$525 | -$473 | -$421 | -$387 |
| AOCI | -$0 | -$0 | $0 | $0 |
| Other Equity | $721 | $713 | $705 | $700 |
| Total Equity | $196 | $240 | $284 | $312 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $322 | $293 | $334 | $370 |
| Net Debt | -$115 | -$43 | -$195 | -$319 |